Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EKSO vs STAA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STAA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–2 Matrix Metrics)

STAA Overall Winner 6-Pillar Tally: EKSO 1 – 5 STAA Matrix Metrics: EKSO 2 – 7 STAA

As of Nov 20, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas STAA carries 42.2/100 (HOLD) at $24.22 (21.4x Forward P/E, 6.8% operating margin).

  • Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STAA 42.2/100 HOLD), STAA captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -119.7% operating margin) and revenue trajectory (-12.0% vs. -38.3% YoY).
  • Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile STAA is in a Breakdown options structure phase (RSI 47.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EKSO vs STAA
EKSO NASDAQ
Ekso Bionics Holdings, Inc. Common Stock
General Industrial Machinery & Equipment, Nec
$11.80
+0.08% 1D
Market Cap $42.0M
TTM Revenue $13M
Forward P/E N/M
Beta / 30D Vol 2.16β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.2% over 20 days), RSI 60
RSI-14: 60.4 · SMA20: $10.56 · SMA50: $10.65
STAA NASDAQ Head-to-Head Winner
Staar Surgical Co
Ophthalmic Goods
$24.22
-3.24% 1D
Market Cap $1.3B
TTM Revenue $328M
Forward P/E 21.4x
Beta / 30D Vol 0.64β · 61% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 33.0 Fund 35.0 Flow 60.0 Mom 11.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.5 · SMA20: $25.27 · SMA50: $23.15

6-Pillar Scorecard Institutional Category Breakdown (EKSO 1 – 5 STAA)

Columns: Metric · EKSO · STAA
1. Valuation Multiples STAA
Forward P/E N/M 21.4x
Trailing P/E N/M N/M
PEG Ratio N/M 0.76x
EV / Revenue 3.3x 3.5x
2. Growth & Scale STAA
Revenue Growth (YoY) -38.3% -12.0%
Earnings Growth (YoY) +0.0% -38.5%
TTM Revenue (USD) $13M $328M
Market Cap $42.0M $1.3B
3. Profitability & Quality STAA
Gross Margin 53.5% 73.6%
Operating Margin -119.7% 6.8%
Net Profit Margin -91.4% 0.2%
Return on Equity (ROE) -107.6% 0.1%
4. Balance Sheet & Cash Flow STAA
Cash Generation (TTM) -$11M EBITDA $18M
Cash Flow Margin -86.0% EBITDA Mgn 5.4%
Net Cash / Leverage $2.54 Book/Sh · -107.6% ROE $100M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EKSO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 179.0% (30th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat STAA
OpEx & R&D Intensity N/A 66.8% of Rev ($219M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EKSO (2) vs STAA (7)
Institutional Metric EKSO STAA Criterion Row Edge
Market Capitalization
Scale
$42.0M $1.3B Larger Scale STAA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M 21.4x Lower Multiple STAA
Revenue Growth (YoY)
Growth
-38.3% -12.0% Higher Growth STAA
Operating Margin (TTM)
Profitability
-119.7% 6.8% Higher Margin STAA
Net Profit Margin
Profitability
-91.4% 0.2% Higher Margin STAA
Return on Equity (ROE)
Capital Efficiency
-107.6% 0.1% Higher ROE STAA
52-Week Range Position
Momentum
87% ($0–$14) 43% ($16–$36) Stronger Trend EKSO
Beta / 30D Volatility
Risk Regime
2.16β · 76% Vol 0.64β · 61% Vol Lower Realized Risk STAA
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite EKSO
Trailing 12M Revenue (USD)
Operating Scale
$13M $328M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
53.5% 73.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev 0.76x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($2.54 Book/Sh · -107.6% ROE) $18M ($100M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STAA +9.5 pp
EKSO: +25.53% · STAA: +35.03%
3M Horizon STAA +25.34 pp
EKSO: +25.93% · STAA: +51.27%
6M Horizon EKSO +189.62 pp
EKSO: +192.8% · STAA: +3.18%
1Y Horizon EKSO +189.62 pp
EKSO: +192.8% · STAA: +3.18%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EKSO vs STAA. Trailing 12-month operating profitability (EKSO -119.7% vs STAA 6.8%) and valuation multiples (EKSO N/M vs STAA 21.4x Forward P/E) are benchmarked directly in Pillar 4 below.

EKSO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin53.5%
Op. Margin-119.7%
ROE / Fwd P/E-107.6% · N/M
STAA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$328M
Gross Margin73.6%
Op. Margin6.8%
ROE / Fwd P/E0.1% · 21.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EKSO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EKSO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
STAA BREAKDOWN
125d in phase · OBV DISTRIBUTION
Current IV 179.0%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact STAA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EKSO Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $42.0M market capitalization and -119.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
STAA Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $1.3B market capitalization and 6.8% operating margin.
OpEx & R&D Reinvestment 66.8% of Rev ($219M)
90D Engineering Disclosures 0 Published

Investor FAQ EKSO vs STAA Key Questions & Quantitative Answers

As of Nov 20, 2026, Staar Surgical Co (STAA) is the stronger overall head-to-head candidate over Ekso Bionics Holdings, Inc. (EKSO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EKSO carries a Unified Composite Score of 58.1/100 (HOLD) at $11.80 (N/M Forward P/E, -119.7% operating margin), whereas STAA carries 42.2/100 (HOLD) at $24.22 (21.4x Forward P/E, 6.8% operating margin). Composite vs. Pillar Nuance: While EKSO currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. STAA 42.2/100 HOLD), STAA captures the overall institutional head-to-head verdict (7–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (6.8% vs. -119.7% operating margin) and revenue trajectory (-12.0% vs. -38.3% YoY). Technical & Structure Timing Caution: EKSO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 60.4); meanwhile STAA is in a Breakdown options structure phase (RSI 47.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

STAA leads the Growth & Scale pillar: EKSO posts -38.3% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (53.5% gross margin, -119.7% operating margin), compared with STAA at -12.0% YoY revenue growth and -38.5% YoY earnings growth on $328M TTM revenue (73.6% gross margin, 6.8% operating margin). On trailing 12-month operating scale, EKSO generates $13M in USD-normalized revenue versus $328M for STAA. In operating R&D and SG&A reinvestment, EKSO deploys N/A (0 90-day corporate R&D disclosures) versus 66.8% of Rev ($219M) (0 disclosures) for STAA.

STAA screens cheaper on headline valuation multiples. EKSO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.3x EV/Revenue (-86.0% EBITDA margin), whereas STAA trades at 21.4x Forward P/E, N/M Trailing P/E, 0.76x PEG, and 3.5x EV/Revenue (5.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EKSO (-107.6% ROE) versus STAA (0.1% ROE) capital efficiency.

In options market volatility and institutional positioning, EKSO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.16β · 76% Vol realized risk). By comparison, STAA carries 179.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.64β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.